205672-24-8

Basic information

• Product Name: (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine
• Synonyms: (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine;5-bromo-2-chloro-N-methyl-4-Pyrimidinamine
• CAS NO: 205672-24-8
• Molecular Formula: C₅H₅BrClN₃
• Molecular Weight: 222.4703
• Mol File: 205672-24-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 366.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.801±0.06 g/cm3(Predicted)
• PKA: 1.33±0.10(Predicted)
• CAS DataBase Reference: (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine(205672-24-8)
• EPA Substance Registry System: (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine(205672-24-8)

Safety Data

• Hazardous Substances Data: 205672-24-8(Hazardous Substances Data)

Usage

General Description

(5-Bromo-2-chloro-pyrimidin-4-yl)-Methyl-amine is a chemical compound with the molecular formula C5H6BrClN3. It is a derivative of pyrimidine and contains bromine, chloro, and methylamine functional groups. (5-BroMo-2-chloro-pyriMidin-4-yl)-Methyl-aMine has potential applications in the field of medicinal chemistry and pharmaceuticals as a building block or intermediate for the synthesis of various bioactive molecules. The specific properties and uses of (5-Bromo-2-chloro-pyrimidin-4-yl)-Methyl-amine can vary depending on its intended application and the structure of the final product.

Upstream product

• 36082-50-5 2,4-dichloro-5-bromopyrimidine 
• 74-89-5 methylamine 

Downstream Products

• 1374828-69-9 2-methyl-2-(3-methyl-4-((4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)propanenitrile 
• 839708-52-0 N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide 
• 839708-51-9 N-{3-[(2-chloro-4-methylaminopyrimidin-5-ylmethyl)amino]-4-methylphenyl}-3-trifluoromethylbenzamide 
• 839708-50-8 2-chloro-4-(methylamino)pyrimidine-5-carbaldehyde 
• 1351759-14-2 (4-(5-bromo-4-(methylamino)pyrimidin-2-ylamino)-3-methoxyphenyl)(morpholino)methanone 

Relevant articles and documents

Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile

Checkpoint kinase 1 (CHK1) plays an important role in the DNA damage response pathway, being a potential anti-cancer drug target. In this study, we used a strategy for trifluoromethyl substitution to obtain orally bioavailable CHK1 inhibitors to overcome the limitations of lead compound 1, which can only be administered intravenously. After detailed investigation, we identified compound 6c as an oral CHK1 inhibitor, which demonstrated a considerably higher plasma exposure in mice. Compound 6c also showed good kinase selectivity. Moreover, it exhibited a significant antiproliferative effect in MV-4-11 cells singly and a synergistic effect in combination with gemcitabine in HT-29, A549, and RPMI-8226 cells. Additionally, compound 6c could inhibit tumor growth in the MV-4-11 xenograft mouse model. The combination of 6c and gemcitabine exhibited synergistic effect in the HT-29 xenograft mouse model. Thus, compound 6c was found to be a selective and oral potential anticancer CHK1 inhibitor.

Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies

Through virtual screening, we identified the lead compound MCL1020, which exhibited modest CHK1 inhibitory activity. Then a series of 5-(pyrimidin-2-ylamino)picolinonitrile derivatives as CHK1 inhibitors were discovered by further rational optimization. One promising molecule, (R)-17, whose potency was one of the best, had an IC50 of 0.4 nM with remarkable selectivity (>4300-fold CHK1 vs. CHK2). Compound (R)-17 effectively inhibited the growth of malignant hematopathy cell lines especially Z-138 (IC50: 0.013 μM) and displayed low affinity for hERG (IC50 > 40 μM). Moreover, (R)-17 significantly suppressed the tumor growth in Z-138 cell inoculated xenograft model (20 mg/kg I.V., TGI = 90.29%) as a single agent with body weight unaffected. Taken together, our data demonstrated compound (R)-17 could be a promising drug candidate for the treatment of hematologic malignancies.

Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2

A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the com